Tech Company Financing Transactions
Epizyme Funding Round
Epizyme, based in Cambridge, secured $8 million in funding from New Enterprise Associates.
Transaction Overview
Company Name
Announced On
12/8/2009
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series B
Investors
New Enterprise Associates (David Mott)
Proceeds Purpose
"By raising more capital now, we can continue to aggressively advance our pipeline of histone methyltransferase inhibitors for various oncology indications. I look forward to working with our investors to continue to build a leading company in the promising new area of epigenetics."
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 4th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company?s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Bazemore
Chief Financial Officer
Paolo Tombesi
Chief Medical Officer
Shefali Agarwal
Chief Operating Officer
Matthew Ros
VP - General Counsel
John Weidenbruch
VP - Regulatory Affairs
Mark De Rosch
Browse more venture capital transactions:
Prev: 12/8/2009: Agilence venture capital transaction
Next: 12/8/2009: Hydro-Photon venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs